Cameron used to head Mylan's compensation committee when
director Robert Coury came under fire for his near $100 million
pay package last year, at a time of growing backlash from U.S.
consumers over the price of the company's life-saving allergy
treatment EpiPen.
More than a third of the investors voting at the generic
drugmaker's annual meeting last year cast votes against Coury,
while over half voted against Cameron.
The company said it had nominated Pauline van der Meer Mohr for
election to its board.
(Reporting by Manas Mishra In Bengaluru; Editing by Savio
D'Souza)
[© 2018 Thomson Reuters. All rights
reserved.] Copyright 2018 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|